RESPIRATORY SYNCYTIAL VIRUS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA vaccine aims to protect older adults from RSV
⭐️ VACCINE ⭐️ OngoingThis study tests a new mRNA vaccine (ABO1105) for respiratory syncytial virus (RSV) in 420 healthy adults aged 50 and older. Participants receive one injection of either a low or high dose of the vaccine or a placebo. The goal is to see how well the vaccine boosts the immune syst…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 19:42 UTC
-
Pregnant RSV shot shields infants: new aussie study
⭐️ VACCINE ⭐️ OngoingThis study looks at how well the RSV vaccine (ABRYSVO) given during pregnancy prevents serious RSV lung infections in babies. Researchers will review health records of infants up to 12 months old who were hospitalized with breathing problems. They will compare RSV test results to…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 19:38 UTC
-
New mRNA vaccine aims to shield adults from RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage trial tests a new mRNA vaccine (ABO1105) against respiratory syncytial virus (RSV) in 96 healthy adults aged 18 and older. The main goal is to check the vaccine's safety and how well the body's immune system responds. Participants receive one injection at one of …
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 19:36 UTC
-
Could a single shot protect babies from two dangerous respiratory viruses?
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests two experimental mRNA vaccines in healthy infants and toddlers aged 5 to 24 months. One vaccine targets both RSV and hMPV, while the other targets only RSV. The main goal is to check safety and how well the vaccines trigger an immune response. About 1…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 15, 2026 11:56 UTC
-
New mRNA vaccine aims to shield newborns from RSV
⭐️ VACCINE ⭐️ OngoingThis study tests an experimental mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) in 360 pregnant women. The goal is to see if vaccinating mothers during late pregnancy (28-36 weeks) is safe and helps pass protection to their babies after birth. Participants wil…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:49 UTC
-
Pregnancy vaccine shields infants from RSV — real-world study launched
⭐️ VACCINE ⭐️ OngoingThis study looks at how effective the ABRYSVO® vaccine is when given to pregnant women to protect their babies from RSV, a serious respiratory virus. Researchers will review medical records of infants up to 9 months old who were hospitalized with breathing problems. The goal is t…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 04, 2026 16:18 UTC